Paper Details

  1. Home
  2. Paper Details

Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.

Author: , ChangSusan M, CloughesyTimothy F, ConradCharles, DanceyJanet, DeAngelisLisa, FinkKaren L, GreenbergHarry, HessKenneth, KuhnJohn G, LambornKathleen R, MehtaMinesh, PradosMichael D, RaizerJeffrey, RobinsH Ian, SchiffDavid, WenPatrick Y

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

This study characterizes the pharmacokinetics of temsirolimus and its major metabolite, sirolimus, in patients receiving enzyme-inducing antiepileptic drugs (EIAED) compared with patients receiving non-EIAEDs. It also aimed to determine whether concentrations of temsirolimus or sirolimus were achieved in brain tumor tissue.
Paper Details　
Original Abstract of the Article :
To characterize the pharmacokinetics of temsirolimus and its major metabolite, sirolimus, in patients receiving enzyme-inducing antiepileptic drugs (EIAED) compared with patients receiving non-EIAEDs. An additional objective was to determine whether concentrations of temsirolimus or sirolimus were a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/18094423

データ提供：米国国立医学図書館（NLM）

Temsirolimus: A New Oasis in the Desert of Malignant Glioma

The desert of malignant glioma is a harsh and unforgiving landscape, with limited treatment options and a poor prognosis. This study investigates the pharmacokinetics of temsirolimus, an anti-cancer drug, in patients with recurrent malignant glioma, focusing on the impact of enzyme-inducing antiepileptic drugs (EIAEDs) on its distribution and effectiveness. The authors analyzed the pharmacokinetic profiles of temsirolimus and its major metabolite, sirolimus, in patients receiving EIAEDs and non-EIAEDs, exploring the potential for drug interactions and their influence on treatment outcomes.

Temsirolimus: A Potential Treatment for Malignant Glioma

The study provides valuable information about the pharmacokinetic profile of temsirolimus in patients with recurrent malignant glioma, demonstrating the potential of this drug as a treatment option. The findings highlight the importance of considering potential drug interactions, particularly with EIAEDs, to optimize treatment outcomes for patients with this challenging condition.

Finding Solutions in the Desert of Cancer

As a desert wanderer, I understand the importance of finding solutions in the face of adversity. This study sheds light on the potential of temsirolimus as a treatment option for malignant glioma, highlighting the need for careful consideration of drug interactions and the importance of individualized treatment plans.

Dr.Camel's Conclusion

This study provides valuable insights into the pharmacokinetics of temsirolimus in patients with recurrent malignant glioma, emphasizing the importance of managing potential drug interactions, particularly with enzyme-inducing antiepileptic drugs. The findings demonstrate the potential of temsirolimus as a treatment option for this challenging condition, but further research is needed to optimize treatment outcomes and improve the prognosis for patients with malignant glioma.

Date :
  1. Date Completed 2008-03-04
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

18094423

DOI: Digital Object Identifier

NIHMS761231

Related Literature

Article Analysis
・Side Effects of temsirolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.